spec sheet10 rows
LSZ ((2'S,4'S)-lysergic acid 2,4-dimethylazetidide) is a lysergamide psychedelic in which the diethylamide of LSD is constrained within a rigid azetidine ring, fixing the amide substituents in a defined orientation. Behavioural characterization using the mouse head-twitch response, a 5-HT2A receptor-mediated proxy for hallucinogenic activity, found LSZ to be essentially equipotent with LSD and to produce a comparable inverted-U dose-response curve. It appeared on the research-chemical market around 2013, typically distributed on blotter paper, and undergoes hepatic N-dealkylation and hydroxylation similar to other lysergamides. Its constrained geometry makes it a useful probe for the conformational requirements of ligand binding at the 5-HT2A receptor.
- Potent, LSD-like visuals
- Often described as forceful and clear
- Somewhat shorter than LSD
- Conformationally locked LSD analog, roughly equipotent in vivo
- Vasoconstriction
- Anxiety possible
- Insomnia after use
Mechanism
LSZ works chiefly as an at the receptor, the receptor central to the psychedelic state, with additional serotonergic activity. Constraining the amide into a 2,4-dimethylazetidine ring holds it in a fixed geometry, which keeps strong 5-HT2A binding and an LSD-like profile. It is an active lysergamide, not a .
receptor fingerprint
receptoragonist
5-HT2C receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
LSZ is a potent, LSD-like psychedelic with little formal safety data, and its more forceful onset can feel intense. Avoid with a personal or family history of psychosis or bipolar disorder, and never combine lysergamides with MAOIs or strongly serotonergic drugs (serotonin toxicity), or with lithium or tramadol (seizure reports). Not medical advice.
Subjective profileweighing the evidence above
Roughly LSD's equal in potency with a somewhat shorter run and a reputation for forceful, clear visuals, so a real psychedelic rather than a novelty. Formal safety data is thin, the onset hits harder than people expect, and at this potency measuring errors are unforgiving.
Resources
This entry is here for reference.
Research
- 2017first citedReturn of the lysergamides. Part II: Analytical and behavioural characterization of N(6) -allyl…
- 2023most recentStimulant and hallucinogenic novel psychoactive substances; an update
- 1.Return of the lysergamides. Part II: Analytical and behavioural characterization of N(6) -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).
- 2.Stimulant and hallucinogenic novel psychoactive substances; an update
- 3.Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ).
- 4.Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products.
- 5.In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures.
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How does LSZ compare to LSD?
It is generally reported as roughly as potent, often with a more forceful, 'pushy' onset and a slightly shorter duration.
What does the azetidine ring do?
It locks LSD's flexible amide into a fixed shape while preserving strong 5-HT2A binding.
Is it a prodrug?
No; LSZ is itself the active lysergamide. This is not medical advice.
Adverse effects
- Vasoconstriction
- Anxiety possible
- Insomnia after use
Notes and cautions
- Intense onset